Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
U.K. To Invest In Genetics, Biologics
by Alex Scott
December 17, 2012
| A version of this story appeared in
Volume 90, Issue 51
The U.K. government has disclosed plans to invest $320 million in a program to map the entire genome of up to 100,000 U.K. patients with cancer and rare diseases and to build a biologic drug manufacturing facility. The U.K. plans to map the genomes within five years and to use the data to develop drugs. As part of the program the government will invest $60 million to create the National Biologics Industrial Innovation Centre, featuring a facility for scaling up biologic drug manufacturing processes.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter